Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Karin Rosen (South San Francisco, United States of America), Nicola A. Hanania, Benjamin Trzaskoma, Karin Rosén, Volkan Manga, Theodore A. Omachi
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases
Abstract Background Response to biologic therapies for the treatment of asthma may be predicted by clinical and biologic markers of asthma severity.Objectives This post-hoc analysis was conducted to determine if clinical markers of asthma severity and blood eosinophils predict response to omalizumab (OMA) treatment for severe allergic asthma.Methods Data were pooled from 2 phase 3, double-blind, randomized, placebo (PBO)-controlled trials of OMA in allergic asthma (N=1071). The number of asthma exacerbations requiring systemic corticosteroids was analyzed over the 16-week-inhaled corticosteroid-stable dose phase of the studies. Effects of OMA on exacerbations in relation to peripheral blood eosinophil counts (<300/m L[low] vs ³ 300/m L[high]), use of long-acting beta agonists (LABAs), and asthma hospitalization in the year prior to screening were examined.Results Exacerbations were reduced 53% with OMA vs PBO (95% CI,33–68;P <0.001) in those requiring systemic corticosteroids; 75% in patients receiving LABAs (95% CI,30-91;P =0.008) compared to 47% not receiving LABAs (95% CI, 23–65; P =0.001); and 63% (95% CI,34–79;P <0.001) with higher blood eosinophils compared to 39% with lower eosinophils (95% CI,0–63;P =0.051). In patients hospitalized for asthma in the year prior to screening, there were no exacerbations in 17 OMA-treated patients and 17 exacerbations in 31 PBO patients, for a 100% reduction (P <0.001). Exacerbations were reduced by 42% in patients not requiring hospitalization in the prior year (95% CI,14–60;P =0.006).Conclusions Patients with greater asthma severity, as assessed by baseline LABA use, prior hospitalizations for asthma, or higher blood eosinophil counts, have a better response to OMA.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Karin Rosen (South San Francisco, United States of America), Nicola A. Hanania, Benjamin Trzaskoma, Karin Rosén, Volkan Manga, Theodore A. Omachi. Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status. Eur Respir J 2015; 46: Suppl. 59, 2952
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: